|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Cervical and Endometrial Cancer - Opportunities remain outside the big gynecologic malignancies
Datamonitor, March 2010, Pages: 101
Introduction
In cervical cancer, screening and human papillomavirus (HPV) vaccination have gradually shifted the focus towards preventative, rather than therapeutic strategies. In endometrial cancer, the focus has been on surgery, as it is considered a surgically-managed disease with a limited role for drug therapy. However, despite these therapeutic attitudes, opportunities remain in both markets.
Scope
-Cervical and endometrial cancer overview, including disease definition, epidemiology, discussion of unmet needs, and market potential
-Current treatment of cervical and endometrial cancer and ongoing controversies
-Examination of the late-phase cervical and endometrial cancer pipeline, including drug profiles of late-stage agents
-Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU
Highlights
Treatment outcomes are still poor for patients with metastatic or recurrent cervical cancer, creating an opportunity for drug developers. The developing countries also offer a large and growing patient base for companies developing cheaper versions of preventative vaccines, diagnostics and pharmaceuticals.
Endometrial cancer is the most common female genital tract malignancy in the US and Europe. Its incidence is expected to rise in the future, in line with the aging population and the increase in the prevalence of conditions such as obesity and diabetes, which have been implicated in the development of the disease.
In recent years, there has been increased interest in the development of molecular targeted therapies for endometrial cancer. This has been coupled with a changing attitude towards the management of the disease, with a greater interest in the role of drug therapy. As a result, the potential of this market may increase in the future.
Reasons to Purchase
-Estimate the number of treatable patients and understand where unmet needs exist for drug development opportunities
-Understand opportunities and threats in the cervical and endometrial cancer markets
-Analyze the current cervical and endometrial cancer pipeline and the potential of late-stage drugs
Customers who bought this item also bought
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact
Cervical Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs
Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy
Cancer Drug Discoveries: What the Future Holds: Non-Small Cell Lung Cancer Chapter
Metastatic Melanoma: Pipeline Assessment and Market Potential Through 2017
Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011
Gastric Cancer Drug Discoveries: What the Future Holds
Drug Delivery in Cancer - Technologies, Markets and Companies
|
|
|
|
